Arjun
IPCT Contributor
Early Detection and Surveillance of the SARS-CoV-2 ...
This report describes early detection and surveillance ...
www.cdc.gov
Pandemic threat? Anyone else concerned?
- Thread starter erkme73
- Start date
www.cdc.gov
Nearly Half of Cancer Patients Taking Ivermectin + Mebendazole
Reported Cancer Disappearance Or Tumor Reduction After 6 Months
Epidemiologist Nicholas Hulscher reported that in the largest study of Ivermectin and Mebendazole anti-parasitic treatments, nearly half of the patients in the study reported a disappearance of the cancer or tumor regression. He wrote that 32.8% of the study participants showed no more evidence of disease after 6 months, 15.6% reported tumor regression and 36.1% reported that the disease had stabilized and was no longer spreading. The clinical program evaluation included 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate). The cancer patients were prescribed compounded ivermectin--mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole---most commonly taken at 1–2 capsules per day.
NOTE: The Need To Know News does not endorse any medical treatments, but instead reports the news. Please consult your own medical health experts before engaging in any medical treatments.
more…
Reported Cancer Disappearance Or Tumor Reduction After 6 Months
Epidemiologist Nicholas Hulscher reported that in the largest study of Ivermectin and Mebendazole anti-parasitic treatments, nearly half of the patients in the study reported a disappearance of the cancer or tumor regression. He wrote that 32.8% of the study participants showed no more evidence of disease after 6 months, 15.6% reported tumor regression and 36.1% reported that the disease had stabilized and was no longer spreading. The clinical program evaluation included 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate). The cancer patients were prescribed compounded ivermectin--mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole---most commonly taken at 1–2 capsules per day.
NOTE: The Need To Know News does not endorse any medical treatments, but instead reports the news. Please consult your own medical health experts before engaging in any medical treatments.
more…
Our Tree guy has a young son who battled cancer, he is cancer free now. What cured him, the same regiment listed in these reports. He actually took the paste you get at feed stores which he stated is a stronger dose.
As bigredfish always states, we are being lied to...
It's getting to the point where I believe and trust the gentlemen and ladies at the feed and seed store a damned sight further than those in the medical community.
Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients
Published April 7, 2026 | Version v1
Abstract
Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity in preclinical models, including the inhibition of cancer cell proliferation and the targeting of cancer stem cells. This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol.
Methods: We analyzed a prospective observational cohort of 197 cancer patients who were prescribed ivermectin and mebendazole off-label through a telemedicine platform by licensed U.S. healthcare providers. Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. As part of a clinical program evaluation, data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) to evaluate self-reported cancer outcomes, medication adherence, and adverse events. 95% confidence intervals (CI) were calculated for primary outcome measures using the Wilson score method. Dose-stratified analyses for outcomes and safety were conducted using Chi-square statistics.
Results: The cohort represented a diverse clinical profile of cancer patients, with mean age of 67 years and nearly balanced sex distribution (52.3% male, 47.7% female). Cancer types included prostate (27.9%), breast (18.3%), lung (8.6%), colon (5.1%), urologic (4.6%), pancreatic (3.0%), liver (2.5%), gynecologic (2.5%), and hematologic (2.5%) malignancies. At enrollment, participants had a median duration since initial diagnosis of 1.2 years, with 37.1% experiencing active disease progression. At 6-month follow-up, medication adherence was high with 86.9% of participants completing the full initial 90-capsule ivermectin-mebendazole prescription and 66.4% remaining on the protocol at 6 months. The Clinical Benefit Ratio (CBR) was 84.4% (95% CI: 77.0--89.8%). Notably, 48.4% (95% CI: 39.7–57.1%) of the cohort reported the strongest positive outcomes, consisting of regression (15.6%; 95% CI: 10.2–23.0%) or no current evidence of disease (NED, 32.8%; 95% CI: 25.1–41.5%). Disease stability was reported to be maintained in 36.1% (95% CI: 28.1–44.9%) of participants, while 15.6% (95% CI: 10.2–23.0%) reported disease progression. While 25.4% reported mild side effects (primarily gastrointestinal), 93.6% of those affected continued treatment through minor dose adjustments. Some participants reported concurrent conventional therapies, including chemotherapy (27.9%), radiation therapy (21.3%), and surgery (19.7%), as well as adjunctive interventions such as supplement use (49.2%), dietary modification (37.7%), and other integrative approaches.
Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumor regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, given the observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials are warranted to validate these observations and further define optimal dosing strategies.
18 page PDF of paper also attached
zenodo.org
Published April 7, 2026 | Version v1
Abstract
Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity in preclinical models, including the inhibition of cancer cell proliferation and the targeting of cancer stem cells. This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol.
Methods: We analyzed a prospective observational cohort of 197 cancer patients who were prescribed ivermectin and mebendazole off-label through a telemedicine platform by licensed U.S. healthcare providers. Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. As part of a clinical program evaluation, data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) to evaluate self-reported cancer outcomes, medication adherence, and adverse events. 95% confidence intervals (CI) were calculated for primary outcome measures using the Wilson score method. Dose-stratified analyses for outcomes and safety were conducted using Chi-square statistics.
Results: The cohort represented a diverse clinical profile of cancer patients, with mean age of 67 years and nearly balanced sex distribution (52.3% male, 47.7% female). Cancer types included prostate (27.9%), breast (18.3%), lung (8.6%), colon (5.1%), urologic (4.6%), pancreatic (3.0%), liver (2.5%), gynecologic (2.5%), and hematologic (2.5%) malignancies. At enrollment, participants had a median duration since initial diagnosis of 1.2 years, with 37.1% experiencing active disease progression. At 6-month follow-up, medication adherence was high with 86.9% of participants completing the full initial 90-capsule ivermectin-mebendazole prescription and 66.4% remaining on the protocol at 6 months. The Clinical Benefit Ratio (CBR) was 84.4% (95% CI: 77.0--89.8%). Notably, 48.4% (95% CI: 39.7–57.1%) of the cohort reported the strongest positive outcomes, consisting of regression (15.6%; 95% CI: 10.2–23.0%) or no current evidence of disease (NED, 32.8%; 95% CI: 25.1–41.5%). Disease stability was reported to be maintained in 36.1% (95% CI: 28.1–44.9%) of participants, while 15.6% (95% CI: 10.2–23.0%) reported disease progression. While 25.4% reported mild side effects (primarily gastrointestinal), 93.6% of those affected continued treatment through minor dose adjustments. Some participants reported concurrent conventional therapies, including chemotherapy (27.9%), radiation therapy (21.3%), and surgery (19.7%), as well as adjunctive interventions such as supplement use (49.2%), dietary modification (37.7%), and other integrative approaches.
Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumor regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, given the observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials are warranted to validate these observations and further define optimal dosing strategies.
18 page PDF of paper also attached
Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort
Abstract Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity in preclinical models, including the inhibition of cancer cell proliferation and the targeting of cancer...
After 18 months taking Ivermectin and Mbenendazole, I'm in the statistical half with no tumor regression or no current evidence of disease. I'm concluding that the data presented was after 6 months on the 2 drugs, but it's a bit difficult for me to pull that number out of the presentation.
The Results: item includes these statistics:
I bolded the section that indicated more than half the participants were on it for six months.
Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients
Published April 7, 2026 | Version v1
Abstract
Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity in preclinical models, including the inhibition of cancer cell proliferation and the targeting of cancer stem cells. This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol.
Methods: We analyzed a prospective observational cohort of 197 cancer patients who were prescribed ivermectin and mebendazole off-label through a telemedicine platform by licensed U.S. healthcare providers. Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. As part of a clinical program evaluation, data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) to evaluate self-reported cancer outcomes, medication adherence, and adverse events. 95% confidence intervals (CI) were calculated for primary outcome measures using the Wilson score method. Dose-stratified analyses for outcomes and safety were conducted using Chi-square statistics.
Results: The cohort represented a diverse clinical profile of cancer patients, with mean age of 67 years and nearly balanced sex distribution (52.3% male, 47.7% female). Cancer types included prostate (27.9%), breast (18.3%), lung (8.6%), colon (5.1%), urologic (4.6%), pancreatic (3.0%), liver (2.5%), gynecologic (2.5%), and hematologic (2.5%) malignancies. At enrollment, participants had a median duration since initial diagnosis of 1.2 years, with 37.1% experiencing active disease progression. At 6-month follow-up, medication adherence was high with 86.9% of participants completing the full initial 90-capsule ivermectin-mebendazole prescription and 66.4% remaining on the protocol at 6 months. The Clinical Benefit Ratio (CBR) was 84.4% (95% CI: 77.0--89.8%). Notably, 48.4% (95% CI: 39.7–57.1%) of the cohort reported the strongest positive outcomes, consisting of regression (15.6%; 95% CI: 10.2–23.0%) or no current evidence of disease (NED, 32.8%; 95% CI: 25.1–41.5%). Disease stability was reported to be maintained in 36.1% (95% CI: 28.1–44.9%) of participants, while 15.6% (95% CI: 10.2–23.0%) reported disease progression. While 25.4% reported mild side effects (primarily gastrointestinal), 93.6% of those affected continued treatment through minor dose adjustments. Some participants reported concurrent conventional therapies, including chemotherapy (27.9%), radiation therapy (21.3%), and surgery (19.7%), as well as adjunctive interventions such as supplement use (49.2%), dietary modification (37.7%), and other integrative approaches.
Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumor regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, given the observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials are warranted to validate these observations and further define optimal dosing strategies.
18 page PDF of paper also attached
Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort
Abstract Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity in preclinical models, including the inhibition of cancer cell proliferation and the targeting of cancer...
I am not putting down this study. I support it. It's just that it's being horribly misinterpreted, as in John Campbell's video title "Ivermectin and mebendazole, 84% benefit in cancer". I'm afraid that most people who see that will think that if they take the Ivermectin/Mbenendazole combination, there's an 84% chance that the cancer they have or might get in the future won't kill them. If you read and understand the study, and the video, there's also a zero percent possibility the combination will help. The study is based on a hypothesis, and shows that the two drugs MIGHT or COULD help. There is no proof whatsoever that they DO help. John's video eventually makes this clear, as does the published study. The video title IMO is unfortunately blatant click bait.
It's largely in the definition of "benefit" in "Clinical Benefit Ratio". In a few cancer cases, the patient improves without any medical intervention whatsoever. This study attributes a case like that as being caused by the Ivermectin/Mebenendazole (I/M) drug combination. 68.9% of the participants were also doing conventional medical intervention. Any improvement or stability caused by that is counted as being caused by the I/M combination. 86.9% of the participants were also doing "other interventions", like behavior and eating changes, or non-prescription supplements. Any benefit caused by them was counted as being caused by the I/M. Another big hole in the study are that the data is all self reported by the participants. I think the only thing that the study proves is that maybe the I/M combination is suspected to help, and it doesn't look like it made anything worse.
After my cancer was diagnosed I was put on a big pharma drug that did a bit of tumor shrinkage and has so far arrested the tumor spread and growth. If I was part of this study, the shrinkage and growth would have been attributed to the I/M combination, which IMO would be 100% false. Based on big pharma clinical trials, the drug I'm on will hold the cancer in check for some amount of time, then it will take off again. It is not expected to cause further tumor shrinkage, or disappearance. It is not touted as a cure. I have the next round of scans in less than a month, and if there is any tumor shrinkage or disappearance, I'll join the ranks of claiming the I/M is responsible, probably, but still no proof.
As John clearly states in the video, only a formal clinical trial will reveal with a high degree of confidence if the I/M combination actually does anything. Since there's no big monetary profit to them, the drug companies aren't going to do it. So unless somebody steps up to risk a lot of their own money to underwrite a trial, the I/M combination helping or curing cancer is just a theory backed up by hope and possibly flawed observations.
It's largely in the definition of "benefit" in "Clinical Benefit Ratio". In a few cancer cases, the patient improves without any medical intervention whatsoever. This study attributes a case like that as being caused by the Ivermectin/Mebenendazole (I/M) drug combination. 68.9% of the participants were also doing conventional medical intervention. Any improvement or stability caused by that is counted as being caused by the I/M combination. 86.9% of the participants were also doing "other interventions", like behavior and eating changes, or non-prescription supplements. Any benefit caused by them was counted as being caused by the I/M. Another big hole in the study are that the data is all self reported by the participants. I think the only thing that the study proves is that maybe the I/M combination is suspected to help, and it doesn't look like it made anything worse.
After my cancer was diagnosed I was put on a big pharma drug that did a bit of tumor shrinkage and has so far arrested the tumor spread and growth. If I was part of this study, the shrinkage and growth would have been attributed to the I/M combination, which IMO would be 100% false. Based on big pharma clinical trials, the drug I'm on will hold the cancer in check for some amount of time, then it will take off again. It is not expected to cause further tumor shrinkage, or disappearance. It is not touted as a cure. I have the next round of scans in less than a month, and if there is any tumor shrinkage or disappearance, I'll join the ranks of claiming the I/M is responsible, probably, but still no proof.
As John clearly states in the video, only a formal clinical trial will reveal with a high degree of confidence if the I/M combination actually does anything. Since there's no big monetary profit to them, the drug companies aren't going to do it. So unless somebody steps up to risk a lot of their own money to underwrite a trial, the I/M combination helping or curing cancer is just a theory backed up by hope and possibly flawed observations.